CERo Therapeutics Holdings Inc. (OTCQB: CERO) dosed the third patient in the second cohort of its Phase 1 CER-1236 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE